Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 568687
                    [Title] => Roche's lung cancer drug receives positive opinion in Europe
                    [Summary] => 
Roche recently announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for use of erlotinib as a maintenance therapy for people with advanced non-small cell lung cancer (NSCLC) and stable disease (cancer remains largely unchanged) after initial chemotherapy.
                    [DatePublished] => 2010-04-23 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 1475655
                    [AuthorName] => LPM
                    [SectionName] => Cebu News
                    [SectionUrl] => cebu-news
                    [URL] => 
                )

        )

)

PROFESSOR FEDERICO CAPPUZZO

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 568687
                    [Title] => Roche's lung cancer drug receives positive opinion in Europe
                    [Summary] => 
Roche recently announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for use of erlotinib as a maintenance therapy for people with advanced non-small cell lung cancer (NSCLC) and stable disease (cancer remains largely unchanged) after initial chemotherapy.
                    [DatePublished] => 2010-04-23 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 1475655
                    [AuthorName] => LPM
                    [SectionName] => Cebu News
                    [SectionUrl] => cebu-news
                    [URL] => 
                )

        )

)

abtest

Roche's lung cancer drug receives positive opinion in Europe

By LPM | April 23, 2010 - 12:00am

Roche recently announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for use of erlotinib as a maintenance therapy for people with advanced non-small cell...

Cebu News